Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina, Inc. (NASDAQ: ILMN) will release its first quarter 2022 financial results on May 5, 2022, after market close. CEO Francis deSouza and CFO Sam Samad will host a conference call at 2:00 PM PT to discuss the results. Interested parties can access the call via Illumina's website or by phone. A replay will be available online for at least 30 days. This announcement highlights Illumina's ongoing commitment to transparency and investor communication.
Illumina has launched a new Solution Center in São Paulo, Brazil, aimed at boosting access to next-generation sequencing training and expertise. This facility underscores Illumina's commitment to expanding genomic access in Latin America amid growing demand for clinical genomics. The 11,000 square-foot center features advanced technology and will host training sessions to optimize user experience. Illumina's long-term engagement in Brazil, including a partnership to track COVID-19, positions it well within the local healthcare market.
Illumina, a leader in DNA sequencing, appointed John Frank as Chief Public Affairs Officer, effective April 18. Frank joins from Microsoft, where he spent 20 years in government affairs. In his new role, he will oversee global government affairs, public policy, patient advocacy, and Corporate Social Responsibility. Frank will advise Illumina's leadership on geopolitical and policy matters affecting the company, aiming to enhance patient access to genomics globally. CEO Francis deSouza emphasized the importance of Frank's expertise in driving impactful change in healthcare.
Illumina (NASDAQ: ILMN) released its 2021 Corporate Social Responsibility (CSR) Report, emphasizing its commitment to environmental, social, and governance (ESG) principles. Key highlights include achieving coverage of 1 billion lives for genomic testing, a commitment to net zero emissions by 2050, and sourcing 59% of global electricity from renewable sources. The company also contributed over $14.5 million to charity, maintained a zero net pay gap, and increased female representation in leadership by 5%. These efforts underline Illumina's role in advancing health equity and sustainability.
Illumina, Inc. (NASDAQ: ILMN) announced the investment in seven new genomics startups as part of its fourth global funding cycle for Illumina Accelerator. This brings the portfolio to 68 startups, with 93% of graduates successfully securing additional capital. The new startups focus on diverse areas like therapeutics, diagnostics, and sustainable foods. Applications for the next funding cycle are due by April 1, 2022. Illumina Accelerator offers seed investments, access to advanced tools, and business guidance to help entrepreneurs drive innovation in genomic medicine.
Illumina launched the TruSight™ Oncology Comprehensive (EU), an advanced in vitro diagnostic test designed for cancer patients in Europe. The test analyzes 517 cancer-related genes and various biomarkers, enhancing precision medicine by delivering molecular profiles quickly—within four to five days. This CE-marked kit aligns with European clinical guidelines and allows for streamlined testing in pathology labs. Clinicians can better match therapies to tumor profiles, thus improving patient outcomes. Illumina aims to expand its oncology partnerships, further advancing cancer diagnostics.
Illumina (NASDAQ: ILMN) has appointed Carissa Rollins as Chief Information Officer as of March 14, 2022. With over 30 years of experience, Rollins previously served at UnitedHealthcare, leading technology strategies across various portfolios. CEO Francis deSouza expressed enthusiasm for her role in enhancing IT innovation and customer experiences. Rollins aims to develop high-performance teams to improve IT services and stakeholder experiences, supporting Illumina's mission of personalized medicine.
Illumina (NASDAQ: ILMN) announced its participation in the Cowen Health Care Conference on March 7, 2022. The company's executives will engage in a fireside chat scheduled for 11:50 AM Pacific Time (2:50 PM Eastern Time), which will be accessible via a live webcast on Illumina's website. A replay will be available for at least 30 days post-event. Illumina is a leader in DNA sequencing and related technologies, aiming to enhance human health through genomic innovation.
GRAIL, a healthcare company focused on early cancer detection, has partnered with Point32Health to pilot its Galleri multi-cancer early detection blood test. This initiative marks Point32Health as the first U.S. commercial health plan to collaborate with GRAIL on this innovative test. The pilot will begin with Point32Health employees and later expand to commercial members, aiming to gather real-world evidence on its effectiveness. Galleri can detect over 50 cancer types with a low false positive rate, potentially saving lives by enabling earlier treatment.
Illumina reported Q4 2021 revenue of $1,198 million, marking a 26% increase year-over-year. GAAP net income was $112 million or $0.71 per diluted share, down from $257 million or $1.75 the previous year. For fiscal 2021, total revenue reached $4,526 million, up 40% from $3,239 million in 2020. However, cash flow from operations fell to $545 million from $1,080 million in the prior year. The company expects consolidated revenue growth between 14% to 16% for 2022 and GAAP earnings per share of $3.04 to $3.24.